{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:44:57Z","timestamp":1790347497298,"version":"4.1.0"},"reference-count":269,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40259-024-00691-0","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T17:19:41Z","timestamp":1734110381000},"page":"75-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Evolving Applications of Bispecific Antibodies: Reaping the Harvest of Early Sowing and Planting New Seeds"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3056-3600","authenticated-orcid":false,"given":"Diego A.","family":"Ellerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"issue":"132","key":"691_CR1","first-page":"1770","volume":"1960","author":"A Nisonoff","year":"1979","unstructured":"Nisonoff A, Wissler FC, Lipman LN. Properties of the major component of a peptic digest of rabbit antibody. Science. 1979;1960(132):1770\u20131.","journal-title":"Science"},{"key":"691_CR2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/0003-9861(61)90296-X","volume":"93","author":"A Nisonoff","year":"1961","unstructured":"Nisonoff A, Rivers MM. Recombination of a mixture of univalent antibody fragments of different specificity. Arch Biochem Biophys. 1961;93:460\u20132.","journal-title":"Arch Biochem Biophys"},{"key":"691_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF02591388","volume":"22","author":"JR Wunderlich","year":"1992","unstructured":"Wunderlich JR, Mezzanzanica D, Garrido MA, Neblock DS, Daddona PE, Andrew SM, et al. Bispecific antibodies and retargeted cellular cytotoxicity: novel approaches to cancer therapy. Int J Clin Lab Res. 1992;22:17\u201320.","journal-title":"Int J Clin Lab Res"},{"key":"691_CR4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585\u2013608.","journal-title":"Nat Rev Drug Discov"},{"key":"691_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/protein\/9.7.617","volume":"9","author":"JB Ridgway","year":"1996","unstructured":"Ridgway JB, Presta LG, Carter P. \u201cKnobs-into-holes\u201d engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996;9:617\u201321.","journal-title":"Protein Eng"},{"key":"691_CR6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nbt0798-677","volume":"16","author":"AM Merchant","year":"1998","unstructured":"Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, et al. An efficient route to human bispecific IgG. Nat Biotechnol. 1998;16:677\u201381.","journal-title":"Nat Biotechnol"},{"key":"691_CR7","doi-asserted-by":"publisher","first-page":"6444","DOI":"10.1073\/pnas.90.14.6444","volume":"90","author":"P Holliger","year":"1993","unstructured":"Holliger P, Prospero T, Winter G. \u201cDiabodies\u201d: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA. 1993;90:6444\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"691_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nbt0297-159","volume":"15","author":"MJ Coloma","year":"1997","unstructured":"Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol. 1997;15:159\u201363.","journal-title":"Nat Biotechnol"},{"key":"691_CR9","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/ijc.25423","volume":"127","author":"MM Heiss","year":"2010","unstructured":"Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial. Int J Cancer. 2010;127:2209\u201321.","journal-title":"Int J Cancer"},{"key":"691_CR10","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ctrv.2010.03.001","volume":"36","author":"D Seimetz","year":"2010","unstructured":"Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM\u00d7anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev. 2010;36:458\u201367.","journal-title":"Cancer Treat Rev"},{"key":"691_CR11","doi-asserted-by":"publisher","first-page":"CMT.S4954","DOI":"10.4137\/CMT.S4954","volume":"2","author":"P Wimberger","year":"2010","unstructured":"Wimberger P, Heubner M, Kimmig R. Catumaxomab in the treatment of malignant ascites: the evidence of its therapeutic value. Clin Med Insights Ther. 2010;2:CMT.S4954.","journal-title":"Clin Med Insights Ther."},{"key":"691_CR12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40259-018-0299-9","volume":"32","author":"B Husain","year":"2018","unstructured":"Husain B, Ellerman D. Expanding the boundaries of biotherapeutics with bispecific antibodies. BioDrugs. 2018;32:441\u201364.","journal-title":"BioDrugs"},{"key":"691_CR13","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","volume":"69","author":"PA Baeuerle","year":"2009","unstructured":"Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69:4941\u20134.","journal-title":"Cancer Res"},{"key":"691_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20131660","volume":"211","author":"N Bien-Ly","year":"2014","unstructured":"Bien-Ly N, Yu YJ, Bumbaca D, Elstrott J, Boswell CA, Zhang Y, et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J Exp Med. 2014;211:233\u201344. https:\/\/doi.org\/10.1084\/jem.20131660.","journal-title":"J Exp Med"},{"key":"691_CR15","doi-asserted-by":"crossref","unstructured":"Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, et al. Therapeutic bispecific antibodies cross the blood\u2013brain barrier in nonhuman primates. Sci Transl Med. 2014;6,261ra154\u2013261ra154","DOI":"10.1126\/scitranslmed.3009835"},{"key":"691_CR16","doi-asserted-by":"crossref","unstructured":"Couch JA, Yu YJ, Zhang Y, Tarrant JM, Fuji RN, Meilandt WJ, et al. Addressing safety liabilities of TfR bispecific antibodies that cross the blood\u2013brain barrier. Sci Transl Med. 2013;5(183):183ra57, 1\u201312","DOI":"10.1126\/scitranslmed.3005338"},{"key":"691_CR17","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1073\/pnas.91.12.5705","volume":"91","author":"JF Poduslo","year":"1994","unstructured":"Poduslo JF, Curran GL, Berg CT. Macromolecular permeability across the blood-nerve and blood\u2013brain barriers. Proc Natl Acad Sci. 1994;91:5705\u20139.","journal-title":"Proc Natl Acad Sci"},{"key":"691_CR18","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s11095-007-9379-0","volume":"24","author":"AR Jones","year":"2007","unstructured":"Jones AR, Shusta EV. Blood\u2013brain barrier transport of therapeutics via receptor-mediation. Pharm Res. 2007;24:1759\u201371.","journal-title":"Pharm Res"},{"key":"691_CR19","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1080\/17425247.2023.2255138","volume":"20","author":"H Baghirov","year":"2023","unstructured":"Baghirov H. Receptor-mediated transcytosis of macromolecules across the blood\u2013brain barrier. Expert Opin Drug Deliv. 2023;20:1699\u2013711.","journal-title":"Expert Opin Drug Deliv"},{"key":"691_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3390\/pharmaceutics14020411","volume":"14","author":"T Tashima","year":"2022","unstructured":"Tashima T. Delivery of intravenously administered antibodies targeting Alzheimer\u2019s disease-relevant tau species into the brain based on receptor-mediated transcytosis. Pharmaceutics. 2022;14:411.","journal-title":"Pharmaceutics"},{"key":"691_CR21","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/pharmaceutics14071335","volume":"14","author":"E Clarke","year":"2022","unstructured":"Clarke E, Stocki P, Sinclair EH, Gauhar A, Fletcher EJR, Krawczun-Rygmaczewska A, et al. A single domain shark antibody targeting the transferrin receptor 1 delivers a TrkB agonist antibody to the brain and provides full neuroprotection in a mouse model of Parkinson\u2019s disease. Pharmaceutics. 2022;14:1335.","journal-title":"Pharmaceutics"},{"key":"691_CR22","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3390\/pharmaceutics14071412","volume":"14","author":"S Roshanbin","year":"2022","unstructured":"Roshanbin S, Julku U, Xiong M, Eriksson J, Masliah E, Hultqvist G, et al. Reduction of \u03b1SYN pathology in a mouse model of PD using a brain-penetrating bispecific antibody. Pharmaceutics. 2022;14:1412.","journal-title":"Pharmaceutics"},{"key":"691_CR23","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1096\/fj.201500078","volume":"30","author":"CI Webster","year":"2016","unstructured":"Webster CI, Caram-Salas N, Haqqani AS, Thom G, Brown L, Rennie K, et al. Brain penetration, target engagement, and disposition of the blood\u2013brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1. FASEB J. 2016;30:1927\u201340.","journal-title":"FASEB J"},{"key":"691_CR24","first-page":"311","volume":"5","author":"P Zhao","year":"2022","unstructured":"Zhao P, Zhang N, An Z. Engineering antibody and protein therapeutics to cross the blood\u2013brain barrier. Antib Ther. 2022;5:311\u201331.","journal-title":"Antib Ther."},{"key":"691_CR25","doi-asserted-by":"crossref","unstructured":"Grimm HP, Schumacher V, Sch\u00e4fer M, Imhof-Jung S, Freskg\u00e5rd P-O, Brady K, et al. Delivery of the BrainshuttleTM amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans. MAbs. 2023;15(1):2261509","DOI":"10.1080\/19420862.2023.2261509"},{"key":"691_CR26","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3390\/pharmaceutics14061240","volume":"14","author":"H Sonoda","year":"2022","unstructured":"Sonoda H, Takahashi K, Minami K, Hirato T, Yamamoto T, So S, et al. Treatment of neuronopathic mucopolysaccharidoses with blood\u2013brain barrier-crossing enzymes: clinical application of receptor-mediated transcytosis. Pharmaceutics. 2022;14:1240.","journal-title":"Pharmaceutics"},{"key":"691_CR27","doi-asserted-by":"crossref","unstructured":"Kariolis MS, Wells RC, Getz JA, Kwan W, Mahon CS, Tong R, et al. Brain delivery of therapeutic proteins using an Fc fragment blood\u2013brain barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020;12(545):eaay1359","DOI":"10.1126\/scitranslmed.aay1359"},{"key":"691_CR28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.chembiol.2023.09.008","volume":"31","author":"G Pornnoppadol","year":"2024","unstructured":"Pornnoppadol G, Bond LG, Lucas MJ, Zupancic JM, Kuo Y-H, Zhang B, et al. Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs. Cell Chem Biol. 2024;31:361-372.e8.","journal-title":"Cell Chem Biol"},{"key":"691_CR29","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1158\/0008-5472.CAN-15-2833","volume":"76","author":"SL Moores","year":"2016","unstructured":"Moores SL, Chiu ML, Bushey BS, Chevalier K, Luistro L, Dorn K, et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 2016;76:3942\u201353.","journal-title":"Cancer Res"},{"key":"691_CR30","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.3390\/jcm13185489","volume":"13","author":"I Papassotiriou","year":"2024","unstructured":"Papassotiriou I, Kapogiannatos A, Makatsoris C, Bakogeorgou S, Mantogiannakou I, Roussou E, et al. Efficacy and safety of amivantamab in advanced or metastatic EGFR-mutant non-small cell lung cancer: a systematic review. J Clin Med. 2024;13:5489.","journal-title":"J Clin Med"},{"key":"691_CR31","doi-asserted-by":"crossref","unstructured":"Rabia E, Garambois V, Dhomm\u00e9e C, Larbouret C, Lajoie L, Buscail Y, et al. Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer. Front Immunol. 2023;14:1168444.","DOI":"10.3389\/fimmu.2023.1168444"},{"key":"691_CR32","doi-asserted-by":"crossref","unstructured":"Kreidieh FY, Tawbi HA, Alexaki A, Borghaei H, Kandalaft LE. Novel immunotherapeutics: perspectives on checkpoints, bispecifics, and vaccines in development. American Society of Clinical Oncology Educational Book; 2023. e391278","DOI":"10.1200\/EDBK_391278"},{"key":"691_CR33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","volume":"17","author":"W Cheng","year":"2024","unstructured":"Cheng W, Kang K, Zhao A, Wu Y. Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer. J Hematol Oncol. 2024;17:54.","journal-title":"J Hematol Oncol"},{"key":"691_CR34","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1038\/s41467-023-38407-7","volume":"14","author":"DW-T Lim","year":"2023","unstructured":"Lim DW-T, Kao H-F, Suteja L, Li CH, Quah HS, Tan DS-W, et al. Clinical efficacy and biomarker analysis of dual PD-1\/CTLA-4 blockade in recurrent\/metastatic EBV-associated nasopharyngeal carcinoma. Nat Commun. 2023;14:2781.","journal-title":"Nat Commun"},{"key":"691_CR35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.20892\/j.issn.2095-3941.2023.0002","volume":"20","author":"T Zhang","year":"2023","unstructured":"Zhang T, Lin Y, Gao Q. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy. Cancer Biol Med. 2023;20:181\u201395.","journal-title":"Cancer Biol Med"},{"key":"691_CR36","doi-asserted-by":"publisher","first-page":"e17515","DOI":"10.1200\/JCO.2023.41.16_suppl.e17515","volume":"41","author":"S Fan","year":"2023","unstructured":"Fan S, Wang T, Zhang Q, Wang J, Su J, Zhang J, et al. The safety and efficacy of cadonilimab in the treatment of advanced and metastatic cervical cancer: a retrospective, real-world study. J Clin Oncol. 2023;41:e17515\u2013e17515.","journal-title":"J Clin Oncol"},{"key":"691_CR37","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.2147\/DDDT.S427416","volume":"17","author":"G Panos","year":"2023","unstructured":"Panos G, Lakshmanan A, Dadoukis P, Ripa M, Motta L, Amoaku W. Faricimab: transforming the future of macular diseases treatment\u2014a comprehensive review of clinical studies. Drug Des Dev Ther. 2023;17:2861\u201373.","journal-title":"Drug Des Dev Ther"},{"key":"691_CR38","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1038\/s41598-024-52942-3","volume":"14","author":"W-T Yen","year":"2024","unstructured":"Yen W-T, Wu C-S, Yang C-H, Chen Y-H, Lee C-H, Hsu C-R. Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis. Sci Rep. 2024;14:2485.","journal-title":"Sci Rep"},{"key":"691_CR39","first-page":"1153","volume":"64","author":"J Lin","year":"2023","unstructured":"Lin J, Correa F, Prasad N, Liu L, Rodriguez M, Ngo M, Williams K, Lu J, Jacobson R, Ngo W, Lin C, Huang X, Pham L, Song K, Liang H, Perlroth V. KSI-501 is a novel anti-VEGF and anti-IL-6 bispecific biopolymer conjugate to simultaneously address neovascularization and inflammation in retinal diseases. Invest Ophthalmol Vis Sci. 2023;64:1153\u20131153.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"691_CR40","first-page":"31","volume":"20","author":"RMGCCMMR R\u00fcckert","year":"2023","unstructured":"R\u00fcckert RMGCCMMR. Bispecific antibodies in retina therapies. Retin Physician. 2023;20:31\u20133.","journal-title":"Retin Physician."},{"key":"691_CR41","doi-asserted-by":"crossref","unstructured":"DiGiandomenico A, Keller AE, Gao C, Rainey GJ, Warrener P, Camara MM, et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014;6: 262ra155","DOI":"10.1126\/scitranslmed.3009655"},{"key":"691_CR42","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1016\/j.ymthe.2024.07.023","volume":"32","author":"R Moirangthem","year":"2024","unstructured":"Moirangthem R, Cordela S, Khateeb D, Shor B, Kosik I, Schneidman-Duhovny D, et al. Dual neutralization of influenza virus hemagglutinin and neuraminidase by a bispecific antibody leads to improved antiviral activity. Mol Ther. 2024;32:3712\u201328.","journal-title":"Mol Ther"},{"key":"691_CR43","doi-asserted-by":"crossref","unstructured":"Ramos KE, Okba NMA, Tan J, Bandawane P, Meade PS, Loganathan M, et al. Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase. mBio. 2024:15:e01085\u201324.","DOI":"10.1128\/mbio.01085-24"},{"key":"691_CR44","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41590-022-01138-w","volume":"23","author":"Z Li","year":"2022","unstructured":"Li Z, Li S, Zhang G, Peng W, Chang Z, Zhang X, et al. An engineered bispecific human monoclonal antibody against SARS-CoV-2. Nat Immunol. 2022;23:423\u201330.","journal-title":"Nat Immunol"},{"key":"691_CR45","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1038\/s41467-024-49096-1","volume":"15","author":"Y Wang","year":"2024","unstructured":"Wang Y, Hao A, Ji P, Ma Y, Zhang Z, Chen J, et al. A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses. Nat Commun. 2024;15:5127.","journal-title":"Nat Commun"},{"key":"691_CR46","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41589-020-00679-1","volume":"17","author":"CJ Bracken","year":"2021","unstructured":"Bracken CJ, Lim SA, Solomon P, Rettko NJ, Nguyen DP, Zha BS, et al. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2. Nat Chem Biol. 2021;17:113\u201321.","journal-title":"Nat Chem Biol"},{"key":"691_CR47","doi-asserted-by":"publisher","first-page":"946","DOI":"10.4161\/mabs.26390","volume":"5","author":"W Tan","year":"2013","unstructured":"Tan W, Meng Y, Li H, Chen Y, Han S, Zeng J, et al. A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity. MAbs. 2013;5:946\u201355.","journal-title":"MAbs"},{"key":"691_CR48","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1080\/19420862.2016.1148850","volume":"8","author":"X Shi","year":"2016","unstructured":"Shi X, Deng Y, Wang H, Ji G, Tan W, Jiang T, et al. A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion. MAbs. 2016;8:574\u201384.","journal-title":"MAbs"},{"key":"691_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.antiviral.2018.11.001","volume":"161","author":"B Zhou","year":"2019","unstructured":"Zhou B, Xu L, Zhu R, Tang J, Wu Y, Su R, et al. A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential. Antiviral Res. 2019;161:28\u201335.","journal-title":"Antiviral Res"},{"key":"691_CR50","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.cell.2016.05.024","volume":"165","author":"Y Huang","year":"2016","unstructured":"Huang Y, Yu J, Lanzi A, Yao X, Andrews CD, Tsai L, et al. Engineered bispecific antibodies with exquisite HIV-1-neutralizing activity. Cell. 2016;165:1621\u201331.","journal-title":"Cell"},{"key":"691_CR51","doi-asserted-by":"crossref","unstructured":"Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature. 1985;314:628\u2013631.","DOI":"10.1038\/314628a0"},{"key":"691_CR52","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/s43018-023-00586-z","volume":"4","author":"RC Bargou","year":"2023","unstructured":"Bargou RC. The expanding success of T cell-engaging bispecific antibodies. Nat Cancer. 2023;4:1054\u20135.","journal-title":"Nat Cancer."},{"issue":"321","key":"691_CR53","first-page":"974","volume":"2008","author":"R Bargou","year":"1979","unstructured":"Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 1979;2008(321):974\u20137.","journal-title":"Science"},{"key":"691_CR54","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","volume":"154","author":"D Ellerman","year":"2019","unstructured":"Ellerman D. Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods. 2019;154:102\u201317.","journal-title":"Methods"},{"key":"691_CR55","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1080\/08820139.2022.2131569","volume":"51","author":"M Long","year":"2022","unstructured":"Long M, Mims AS, Li Z. Factors affecting the cancer immunotherapeutic efficacy of t cell bispecific antibodies and strategies for improvement. Immunol Invest. 2022;51:2176\u2013214.","journal-title":"Immunol Invest"},{"key":"691_CR56","doi-asserted-by":"publisher","first-page":"LBA-1","DOI":"10.1182\/blood-2022-171751","volume":"140","author":"MR Litzow","year":"2022","unstructured":"Litzow MR, Sun Z, Paietta E, Mattison RJ, Lazarus HM, Rowe JM, et al. Consolidation therapy with blinatumomab improves overall survival in newly diagnosed adult patients with B-lineage acute lymphoblastic leukemia in measurable residual disease negative remission: results from the ECOG-ACRIN E1910 randomized phase III National Cooperative Clinical Trials Network Trial. Blood. 2022;140:LBA-1.","journal-title":"Blood"},{"key":"691_CR57","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41408-022-00766-7","volume":"13","author":"N Boissel","year":"2023","unstructured":"Boissel N, Chiaretti S, Papayannidis C, Ribera J-M, Bassan R, Sokolov AN, et al. Real-world use of blinatumomab in adult patients with B-cell acute lymphoblastic leukemia in clinical practice: results from the NEUF study. Blood Cancer J. 2023;13:2.","journal-title":"Blood Cancer J"},{"key":"691_CR58","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1200\/JCO.22.01725","volume":"41","author":"C Thieblemont","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023;41:2238\u201347.","journal-title":"J Clin Oncol"},{"key":"691_CR59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-023-01462-0","volume":"16","author":"Y Cao","year":"2023","unstructured":"Cao Y, Marcucci EC, Budde LE. Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting. J Hematol Oncol. 2023;16:69.","journal-title":"J Hematol Oncol"},{"key":"691_CR60","doi-asserted-by":"publisher","first-page":"e49668c2","DOI":"10.1097\/01.HS9.0000975796.49668.c2","volume":"7","author":"U Vitolo","year":"2023","unstructured":"Vitolo U, Phillips EH, Alonso AA, Merli M, Risal A, Namuduri M, et al. PB2266: trial in progress: phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed\/refractory follicular lymphoma and marginal zone lymphoma (OLYMPIA-5). Hemasphere. 2023;7:e49668c2.","journal-title":"Hemasphere."},{"key":"691_CR61","doi-asserted-by":"publisher","first-page":"163","DOI":"10.6004\/jadpro.2023.14.2.7","volume":"14","author":"PBG Hua","year":"2023","unstructured":"Hua PBG, Scanlan PCR, Straining PBR, Carlson DDS. Teclistamab-cqyv: the first bispecific T-cell engager antibody for the treatment of patients with relapsed or refractory multiple myeloma. J Adv Pract Oncol. 2023;14:163\u201371.","journal-title":"J Adv Pract Oncol"},{"key":"691_CR62","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-023-01489-3","volume":"16","author":"J Zhao","year":"2023","unstructured":"Zhao J, Ren Q, Liu X, Guo X, Song Y. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting. J Hematol Oncol. 2023;16:92.","journal-title":"J Hematol Oncol"},{"key":"691_CR63","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.3390\/cancers13164113","volume":"13","author":"FM Uckun","year":"2021","unstructured":"Uckun FM, Lin TL, Mims AS, Patel P, Lee C, Shahidzadeh A, et al. A clinical phase 1B study of the CD3xCD123 bispecific antibody APVO436 in patients with relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome. Cancers (Basel). 2021;13:4113.","journal-title":"Cancers (Basel)."},{"key":"691_CR64","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-21-0470","volume":"27","author":"AJ Van De Vyver","year":"2021","unstructured":"Van De Vyver AJ, Marrer-Berger E, Wang K, Lehr T, Walz A-C. Cytokine release syndrome by T-cell-redirecting therapies: can we predict and modulate patient risk? Clin Cancer Res. 2021;27:6083\u201394.","journal-title":"Clin Cancer Res"},{"key":"691_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003766","volume":"10","author":"G Leclercq","year":"2022","unstructured":"Leclercq G, Haegel H, Toso A, Zimmermann T, Green L, Steinhoff N, et al. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. J Immunother Cancer. 2022;10: e003766.","journal-title":"J Immunother Cancer"},{"key":"691_CR66","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/14712598.2023.2166786","volume":"23","author":"G Leclercq-cohen","year":"2023","unstructured":"Leclercq-cohen G, Bacac M, Klein C. Rationale for combining tyrosine kinase inhibitors and T cell redirecting antibodies to mitigate cytokine release syndrome (CRS). Expert Opin Biol Ther. 2023;23:223\u20135.","journal-title":"Expert Opin Biol Ther"},{"key":"691_CR67","doi-asserted-by":"crossref","unstructured":"Leclercq G, Steinhoff N, Haegel H, De Marco D, Bacac M, Klein C. Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. Oncoimmunology. 2022;11(1):2083479","DOI":"10.1080\/2162402X.2022.2083479"},{"key":"691_CR68","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41540-020-00145-7","volume":"6","author":"I Hosseini","year":"2020","unstructured":"Hosseini I, Gadkar K, Stefanich E, Li C-C, Sun LL, Chu Y-W, et al. Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20\/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020;6:28.","journal-title":"NPJ Syst Biol Appl."},{"key":"691_CR69","doi-asserted-by":"crossref","unstructured":"Vafa O, Trinklein ND. Perspective: designing T-cell engagers with better therapeutic windows. Front Oncol. 2020;10:446.","DOI":"10.3389\/fonc.2020.00446"},{"key":"691_CR70","doi-asserted-by":"publisher","first-page":"14397","DOI":"10.1038\/s41598-021-93842-0","volume":"11","author":"L Haber","year":"2021","unstructured":"Haber L, Olson K, Kelly MP, Crawford A, DiLillo DJ, Tavar\u00e9 R, et al. Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning. Sci Rep. 2021;11:14397.","journal-title":"Sci Rep"},{"key":"691_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002488","volume":"9","author":"K Dang","year":"2021","unstructured":"Dang K, Castello G, Clarke SC, Li Y, Balasubramani A, Boudreau A, et al. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release. J Immunother Cancer. 2021;9: e002488.","journal-title":"J Immunother Cancer"},{"key":"691_CR72","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/19420862.2019.1574521","volume":"11","author":"ND Trinklein","year":"2019","unstructured":"Trinklein ND, Pham D, Schellenberger U, Buelow B, Boudreau A, Choudhry P, et al. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies. MAbs. 2019;11:639\u201352.","journal-title":"MAbs"},{"key":"691_CR73","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.1182\/blood-2022-165817","volume":"140","author":"L Liu","year":"2022","unstructured":"Liu L, Li G, Wang L, Yakkundi P, Hinton PR, Pandya D, et al. CD123 Directed IgM antibody-based T-cell engager, IGM-2537, demonstrates potent in vitro and in vivo activity with minimal cytokine release. Blood. 2022;140:5918\u20139.","journal-title":"Blood"},{"key":"691_CR74","doi-asserted-by":"crossref","unstructured":"Kwant K, Rocha S, Stephenson K, Dayao M, Thothathri S, Banzon R, et al. 867\u2005TriTAC-XR is an extended-release T cell engager platform designed to minimize cytokine release syndrome by reducing Cmax in systemic circulation. Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2021. p. A908\u2013A908.","DOI":"10.1136\/jitc-2021-SITC2021.867"},{"key":"691_CR75","doi-asserted-by":"crossref","unstructured":"Tu G, Shen W, Yang Z, Xue S, Tan Y, Xie B, et al. 1188 In vitro and in vivo characterization of CD8 + T cell engagers (TCEs) for cancer immunotherapy. Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2023. p. A1308\u2013A1308.","DOI":"10.1136\/jitc-2023-SITC2023.1188"},{"key":"691_CR76","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41408-017-0023-x","volume":"7","author":"E Mejstr\u00edkov\u00e1","year":"2017","unstructured":"Mejstr\u00edkov\u00e1 E, Hrusak O, Borowitz MJ, Whitlock JA, Brethon B, Trippett TM, et al. CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 2017;7:659.","journal-title":"Blood Cancer J"},{"key":"691_CR77","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","volume":"14","author":"M Ruella","year":"2016","unstructured":"Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J. 2016;14:357\u201362.","journal-title":"Comput Struct Biotechnol J"},{"key":"691_CR78","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1182\/blood-2020-137499","volume":"136","author":"J Brouwer-Visser","year":"2020","unstructured":"Brouwer-Visser J, Fiaschi N, Deering RP, Dhanik A, Cygan KJ, Zhang W, et al. Baseline biomarkers of T-cell function correlate with clinical responses to odronextamab (REGN1979), and loss of CD20 target antigen expression identified as a mechanism of treatment resistance. Blood. 2020;136:10\u20131.","journal-title":"Blood"},{"key":"691_CR79","doi-asserted-by":"publisher","first-page":"7526","DOI":"10.1200\/JCO.2022.40.16_suppl.7526","volume":"40","author":"SJ Schuster","year":"2022","unstructured":"Schuster SJ, Huw L-Y, Bolen CR, Assouline SE, Bartlett NL, Budde LE, et al. Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed\/refractory B-cell non-Hodgkin lymphomas. J Clin Oncol. 2022;40:7526\u20137526.","journal-title":"J Clin Oncol"},{"key":"691_CR80","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023;41:711-725.e6.","journal-title":"Cancer Cell"},{"key":"691_CR81","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.omto.2023.02.004","volume":"28","author":"DH Park","year":"2023","unstructured":"Park DH, Liaw K, Bhojnagarwala P, Zhu X, Choi J, Ali AR, et al. Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape. Mol Ther Oncol. 2023;28:249\u201363.","journal-title":"Mol Ther Oncol."},{"key":"691_CR82","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.7150\/thno.81494","volume":"13","author":"A Tapia-Galisteo","year":"2023","unstructured":"Tapia-Galisteo A, Compte M, \u00c1lvarez-Vallina L, Sanz L. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy. Theranostics. 2023;13:1028\u201341.","journal-title":"Theranostics."},{"key":"691_CR83","doi-asserted-by":"crossref","unstructured":"Tapia-Galisteo A, S\u00e1nchez Rodr\u00edguez \u00cd, Aguilar-Sope\u00f1a O, Harwood SL, Narbona J, Ferreras Gutierrez M, et al. Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer. Oncoimmunology. 2022;11(1):2034355.","DOI":"10.1080\/2162402X.2022.2034355"},{"key":"691_CR84","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007398","volume":"11","author":"K Meetze","year":"2023","unstructured":"Meetze K, Mehta NK, Li B, Findlay HM, London TB, Patakas A, et al. CLN-978, a novel half-life extended CD19\/CD3\/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression. J Immunother Cancer. 2023;11: e007398.","journal-title":"J Immunother Cancer"},{"key":"691_CR85","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29:3044\u201360.","journal-title":"Curr Oncol"},{"key":"691_CR86","doi-asserted-by":"publisher","unstructured":"Kobold S, Pantelyushin S, Rataj F, vom Berg J. Rationale for combining bispecific T cell activating antibodies with checkpoint blockade for cancer therapy. Front Oncol. 2018;8. https:\/\/doi.org\/10.3389\/fonc.2018.00285.","DOI":"10.3389\/fonc.2018.00285"},{"key":"691_CR87","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/leu.2015.214","volume":"30","author":"C Krupka","year":"2016","unstructured":"Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, K\u00f6hnke T, et al. Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia. 2016;30:484\u201391.","journal-title":"Leukemia"},{"key":"691_CR88","doi-asserted-by":"publisher","first-page":"iii151","DOI":"10.1093\/annonc\/mdx302.003","volume":"28","author":"G Argil\u00e9s","year":"2017","unstructured":"Argil\u00e9s G, Saro J, Segal NH, Melero I, Ros W, Marabelle A, et al. Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC). Ann Oncol. 2017;28:iii151.","journal-title":"Ann Oncol"},{"key":"691_CR89","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1182\/blood-2023-191109","volume":"142","author":"JA Webster","year":"2023","unstructured":"Webster JA, Luskin MR, Rimando J, Blackford A, Zeidan AM, Sharon E, et al. Blinatumomab in combination with immune checkpoint inhibitors (ICIs) of PD-1 and CTLA-4 in adult patients with relapsed\/refractory (R\/R) CD19 positive B-cell acute lymphoblastic leukemia (ALL): results of a phase I study. Blood. 2023;142:966\u2013966.","journal-title":"Blood"},{"key":"691_CR90","doi-asserted-by":"publisher","unstructured":"Wunderlich M, Manning N, Sexton C, O\u2019Brien E, Byerly L, Stillwell C, et al. PD-1 inhibition enhances blinatumomab response in a UCB\/PDX model of relapsed pediatric B-cell acute lymphoblastic leukemia. Front Oncol. 2021;11. https:\/\/doi.org\/10.3389\/fonc.2021.642466.","DOI":"10.3389\/fonc.2021.642466"},{"key":"691_CR91","doi-asserted-by":"crossref","unstructured":"Zhu WM, Middleton MR. Combination therapies for the optimisation of bispecific T-cell engagers in cancer treatment. Immunother Adv. 2023; 3(1):ltad013.","DOI":"10.1093\/immadv\/ltad013"},{"key":"691_CR92","doi-asserted-by":"publisher","first-page":"LB-153","DOI":"10.1158\/1538-7445.AM2018-LB-153","volume":"78","author":"RC Sainson","year":"2018","unstructured":"Sainson RC, Parveen N, Borhis G, Kosmac M, OKell T, Taggart E, et al. Abstract LB-153: KY1055, a novel ICOS-PD-L1 bispecific antibody, efficiently enhances T cell activation and delivers a potent anti-tumour response in vivo. Cancer Res. 2018;78:LB-153.","journal-title":"Cancer Res"},{"key":"691_CR93","doi-asserted-by":"publisher","first-page":"TPS9595","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9595","volume":"41","author":"S Jacob","year":"2023","unstructured":"Jacob S, Daud A. Phase Ib\/II study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint inhibitor therapy with and without CNS disease. J Clin Oncol. 2023;41:TPS9595.","journal-title":"J Clin Oncol"},{"key":"691_CR94","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4155\/ppa-2020-0035","volume":"10","author":"M Perez-Santos","year":"2021","unstructured":"Perez-Santos M, Anaya-Ruiz M, Sanchez-Esgua G, Villafa\u00f1a-Diaz L, Barron-Villaverde D. Treatment of solid tumors using bispecific anti-PDL-1\/ICOS antibody. Pharm Pat Anal. 2021;10:67\u201372.","journal-title":"Pharm Pat Anal."},{"key":"691_CR95","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1158\/1538-7445.AM2019-4077","volume":"79","author":"S Fritzell","year":"2019","unstructured":"Fritzell S, Levin M, \u00c5berg I, Johansson M, Winnerstam M, Smith KE, et al. Abstract 4077: ATOR-1144 is a tumor-directed CTLA-4 x GITR bispecific antibody that acts by depleting Tregs and activating effector T cells and NK cells. Cancer Res. 2019;79:4077\u20134077.","journal-title":"Cancer Res"},{"key":"691_CR96","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/13543776.2020.1732352","volume":"30","author":"L Mill\u00e1n-P\u00e9rez Pe\u00f1a","year":"2020","unstructured":"Mill\u00e1n-P\u00e9rez Pe\u00f1a L, Martin P-S, Herrera-Camacho I, Bandala C, Anaya-Ruiz M. Colon carcinoma treatment using bispecific anti-GITR\/CTLA-4 antibodies: a patent evaluation of WO2018091739. Expert Opin Ther Pat. 2020;30:307\u201311.","journal-title":"Expert Opin Ther Pat"},{"key":"691_CR97","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s43018-022-00334-9","volume":"3","author":"S Chan","year":"2022","unstructured":"Chan S, Belmar N, Ho S, Rogers B, Stickler M, Graham M, et al. An anti-PD-1\u2013GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy. Nat Cancer. 2022;3:337\u201354.","journal-title":"Nat Cancer."},{"key":"691_CR98","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006348","volume":"11","author":"C Demerl\u00e9","year":"2023","unstructured":"Demerl\u00e9 C, Gorvel L, Mello M, Pastor S, Degos C, Zarubica A, et al. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors. J Immunother Cancer. 2023;11: e006348.","journal-title":"J Immunother Cancer"},{"key":"691_CR99","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40425-019-0570-8","volume":"7","author":"AM Kvarnhammar","year":"2019","unstructured":"Kvarnhammar AM, Veitonm\u00e4ki N, H\u00e4gerbrand K, Dahlman A, Smith KE, Fritzell S, et al. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. J Immunother Cancer. 2019;7:103.","journal-title":"J Immunother Cancer"},{"key":"691_CR100","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-20-0226","volume":"19","author":"Z Kuang","year":"2020","unstructured":"Kuang Z, Pu P, Wu M, Wu Z, Wang L, Li Y, et al. A novel bispecific antibody with PD-L1-assisted OX40 activation for cancer treatment. Mol Cancer Ther. 2020;19:2564\u201374.","journal-title":"Mol Cancer Ther"},{"key":"691_CR101","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa063842","volume":"355","author":"G Suntharalingam","year":"2006","unstructured":"Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. NEJM. 2006;355:1018\u201328.","journal-title":"NEJM"},{"key":"691_CR102","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1476-5381.2010.00922.x","volume":"161","author":"D Eastwood","year":"2010","unstructured":"Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M, Moore M, et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T-cells. Br J Pharmacol. 2010;161:512\u201326.","journal-title":"Br J Pharmacol"},{"key":"691_CR103","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.imlet.2005.06.012","volume":"100","author":"T H\u00fcnig","year":"2005","unstructured":"H\u00fcnig T, Dennehy K. CD28 superagonists: mode of action and therapeutic potential. Immunol Lett. 2005;100:21\u20138.","journal-title":"Immunol Lett"},{"key":"691_CR104","doi-asserted-by":"crossref","unstructured":"Skokos D, Waite JC, Haber L, Crawford A, Hermann A, Ullman E, et al. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies. Sci Transl Med. 2020;12:eaba2325.","DOI":"10.1126\/scitranslmed.aaw7888"},{"key":"691_CR105","doi-asserted-by":"crossref","unstructured":"Waite JC, Wang B, Haber L, Hermann A, Ullman E, Ye X, et al. Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy. Sci Transl Med. 2020;12(549):eaba2325.","DOI":"10.1126\/scitranslmed.aba2325"},{"key":"691_CR106","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1200\/JCO.2023.41.6_suppl.154","volume":"41","author":"MN Stein","year":"2023","unstructured":"Stein MN, Zhang J, Kelly WK, Wise DR, Tsao K, Carneiro BA, et al. Preliminary results from a phase 1\/2 study of co-stimulatory bispecific PSMAxCD28 antibody REGN5678 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2023;41:154\u2013154.","journal-title":"J Clin Oncol"},{"key":"691_CR107","unstructured":"Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, et al. Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Sci Transl Med. 2019;2;11(496):eaav5989."},{"key":"691_CR108","doi-asserted-by":"crossref","unstructured":"Melero I, Tanos T, Bustamante M, Sanmamed MF, Calvo E, Moreno I, et al. A first-in-human study of the fibroblast activation protein\u2013targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Sci Transl Med. 2023;15(695):eabp9229.","DOI":"10.1126\/scitranslmed.abp9229"},{"key":"691_CR109","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1158\/1538-7445.AM2023-2971","volume":"83","author":"M Sarkar","year":"2023","unstructured":"Sarkar M, Tam EM, Jin G, Chin SS, Abulizi A, Sergeeva OA, et al. Abstract 2971: EVOLVETM: a novel T cell engager platform with integrated CD2 costimulation engineered for the treatment of immune suppressive tumors. Cancer Res. 2023;83:2971\u20132971.","journal-title":"Cancer Res"},{"key":"691_CR110","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.1038\/s41467-021-27613-w","volume":"12","author":"I Otano","year":"2021","unstructured":"Otano I, Azpilikueta A, Glez-Vaz J, Alvarez M, Medina-Echeverz J, Cort\u00e9s-Dom\u00ednguez I, et al. CD137 (4\u20131BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. Nat Commun. 2021;12:7296.","journal-title":"Nat Commun"},{"issue":"283","key":"691_CR111","first-page":"649","volume":"1999","author":"ML Dustin","year":"1979","unstructured":"Dustin ML, Shaw AS. Costimulation: building an immunological synapse. Science. 1979;1999(283):649\u201350.","journal-title":"Science"},{"key":"691_CR112","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nri3066","volume":"11","author":"ML Dustin","year":"2011","unstructured":"Dustin ML, Depoil D. New insights into the T cell synapse from single molecule techniques. Nat Rev Immunol. 2011;11:672\u201384.","journal-title":"Nat Rev Immunol"},{"key":"691_CR113","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.immuni.2008.08.011","volume":"29","author":"T Yokosuka","year":"2008","unstructured":"Yokosuka T, Kobayashi W, Sakata-Sogawa K, Takamatsu M, Hashimoto-Tane A, Dustin ML, et al. Spatiotemporal regulation of T cell costimulation by TCR-CD28 microclusters and protein kinase C \u03b8 translocation. Immunity. 2008;29:589\u2013601.","journal-title":"Immunity"},{"key":"691_CR114","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","volume":"18","author":"R Spolski","year":"2018","unstructured":"Spolski R, Li P, Leonard WJ. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat Rev Immunol. 2018;18:648\u201359.","journal-title":"Nat Rev Immunol"},{"key":"691_CR115","doi-asserted-by":"crossref","unstructured":"Waldhauer I, Gonzalez-Nicolini V, Freimoser-Grundschober A, Nayak TK, Fahrni L, Hosse RJ, et al. Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. MAbs. 2021;13(1):1913791.","DOI":"10.1080\/19420862.2021.1913791"},{"key":"691_CR116","doi-asserted-by":"crossref","unstructured":"Hsu J, Donahue RN, Katragadda M, Lowry J, Huang W, Srinivasan K, et al. A T cell receptor \u03b2 chain\u2013directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity. Sci Transl Med. 2023;15(724):eadi0258.","DOI":"10.1126\/scitranslmed.adi0258"},{"key":"691_CR117","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/s41422-021-00543-4","volume":"31","author":"J Guo","year":"2021","unstructured":"Guo J, Liang Y, Xue D, Shen J, Cai Y, Zhu J, et al. Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity. Cell Res. 2021;31:1190\u20138.","journal-title":"Cell Res"},{"key":"691_CR118","doi-asserted-by":"publisher","first-page":"7311","DOI":"10.3390\/ijms23137311","volume":"23","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Husman T, Cen X, Tsao T, Brown J, Bajpai A, et al. Interleukin 15 in cell-based cancer immunotherapy. Int J Mol Sci. 2022;23:7311.","journal-title":"Int J Mol Sci"},{"key":"691_CR119","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3892\/etm.2021.10107","volume":"22","author":"G Isvoranu","year":"2021","unstructured":"Isvoranu G, Surcel M, Munteanu A, Bratu O, Ionita-Radu F, Neagu M, et al. Therapeutic potential of interleukin-15 in cancer (Review). Exp Ther Med. 2021;22:675.","journal-title":"Exp Ther Med"},{"key":"691_CR120","doi-asserted-by":"crossref","unstructured":"Wo J, Zhang F, Li Z, Sun C, Zhang W, Sun G. The role of gamma-delta T cells in diseases of the central nervous system. Front Immunol. 2020; 11:580304.","DOI":"10.3389\/fimmu.2020.580304"},{"key":"691_CR121","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1158\/2159-8290.CD-13-0985","volume":"4","author":"I Melero","year":"2014","unstructured":"Melero I, Rouzaut A, Motz GT, Coukos G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov. 2014;4:522\u20136.","journal-title":"Cancer Discov"},{"key":"691_CR122","unstructured":"Boutin L, Barjon C, Lafrance L, Senechal E, Bourges D, Vigne E, et al. Targeting human \u03b3\u03b4 T cells as a potent and safe alternative to pan-T cells bispecific cell engagers. bioRxiv [Internet]. 2023;2023.07.10.548307. Available from: http:\/\/biorxiv.org\/content\/early\/2023\/07\/11\/2023.07.10.548307.abstract."},{"key":"691_CR123","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.celrep.2014.04.049","volume":"7","author":"EP Dopfer","year":"2014","unstructured":"Dopfer EP, Hartl FA, Oberg H-H, Siegers GM, Yousefi OS, Kock S, et al. The CD3 conformational change in the \u03b3\u03b4 T cell receptor is not triggered by antigens but can be enforced to enhance tumor killing. Cell Rep. 2014;7:1704\u201315.","journal-title":"Cell Rep"},{"key":"691_CR124","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1200\/JCO.2023.41.6_suppl.153","volume":"41","author":"N Mehra","year":"2023","unstructured":"Mehra N, Robbrecht D, Voortman J, Parren PW, Macia S, Veeneman J, et al. Early dose escalation of LAVA-1207, a novel bispecific gamma-delta T-cell engager (Gammabody), in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2023;41:153\u2013153.","journal-title":"J Clin Oncol"},{"key":"691_CR125","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1182\/blood-2022-166851","volume":"140","author":"AP Kater","year":"2022","unstructured":"Kater AP, Van De Donk NWCJ, Rodr\u00edguez-Otero P, Mateos MV, Bosch F, Tucci A, et al. Lava-051, a novel bispecific gamma-delta T-cell engager (Gammabody), in relapsed\/refractory MM and CLL: pharmacodynamic and early clinical data. Blood. 2022;140:4608\u20139.","journal-title":"Blood"},{"key":"691_CR126","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1038\/s41375-021-01122-7","volume":"35","author":"R Ganesan","year":"2021","unstructured":"Ganesan R, Chennupati V, Ramachandran B, Hansen MR, Singh S, Grewal IS. Selective recruitment of \u03b3\u03b4 T cells by a bispecific antibody for the treatment of acute myeloid leukemia. Leukemia. 2021;35:2274\u201384.","journal-title":"Leukemia"},{"key":"691_CR127","doi-asserted-by":"publisher","first-page":"6722","DOI":"10.1158\/1538-7445.AM2024-6722","volume":"84","author":"AY Lai","year":"2024","unstructured":"Lai AY, Wang C, Baiu DC, Smith K, Patel A, Evans K, et al. Abstract 6722: a CD33 antigen targeted Gamma Delta T-cell engager in combination with zoledronate promotes Vg9Vd2+ T cell proliferation and cytotoxicity against acute myeloid leukemia. Cancer Res. 2024;84:6722\u20136722.","journal-title":"Cancer Res"},{"key":"691_CR128","doi-asserted-by":"crossref","unstructured":"Vantourout P, Eum J, Conde Poole M, Hayday TS, Laing AG, Hussain K, et al. Innate TCR\u03b2-chain engagement drives human T cells toward distinct memory-like effector phenotypes with immunotherapeutic potentials. Sci Adv. 2023;9(49):eadj6174.","DOI":"10.1126\/sciadv.adj6174"},{"key":"691_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101161","volume":"4","author":"M Boulch","year":"2023","unstructured":"Boulch M, Cazaux M, Cuffel A, Ruggiu M, Allain V, Corre B, et al. A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy. Cell Rep Med. 2023;4: 101161.","journal-title":"Cell Rep Med."},{"key":"691_CR130","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005878","volume":"11","author":"C Bove","year":"2023","unstructured":"Bove C, Arcangeli S, Falcone L, Camisa B, El Khoury R, Greco B, et al. CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses. J Immunother Cancer. 2023;11: e005878.","journal-title":"J Immunother Cancer"},{"key":"691_CR131","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-023-01714-0","volume":"22","author":"M Iglesias-Escudero","year":"2023","unstructured":"Iglesias-Escudero M, Arias-Gonz\u00e1lez N, Mart\u00ednez-C\u00e1ceres E. Regulatory cells and the effect of cancer immunotherapy. Mol Cancer. 2023;22:26.","journal-title":"Mol Cancer"},{"key":"691_CR132","doi-asserted-by":"crossref","unstructured":"Belmontes B, Sawant D V., Zhong W, Tan H, Kaul A, Aeffner F, et al. Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell\u2013cold solid tumors. Sci Transl Med. 2021;13(608):eabd1524.","DOI":"10.1126\/scitranslmed.abd1524"},{"key":"691_CR133","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2017.41","volume":"31","author":"J Duell","year":"2017","unstructured":"Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A, et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 2017;31:2181\u201390.","journal-title":"Leukemia"},{"key":"691_CR134","doi-asserted-by":"crossref","unstructured":"Casey M, Lee C, Kwok WY, Law SC, Corvino D, Gandhi MK, et al. Regulatory T cells hamper the efficacy of T-cell engaging bispecific antibody therapy. Haematologica. 2024;109(3):787\u201398.","DOI":"10.3324\/haematol.2023.283758"},{"key":"691_CR135","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.1038\/s41598-022-09458-5","volume":"12","author":"M Haruna","year":"2022","unstructured":"Haruna M, Ueyama A, Yamamoto Y, Hirata M, Goto K, Yoshida H, et al. The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer. Sci Rep. 2022;12:5377.","journal-title":"Sci Rep"},{"key":"691_CR136","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/eji.202048992","volume":"51","author":"S Dees","year":"2021","unstructured":"Dees S, Ganesan R, Singh S, Grewal IS. Regulatory T cell targeting in cancer: emerging strategies in immunotherapy. Eur J Immunol. 2021;51:280\u201391.","journal-title":"Eur J Immunol"},{"key":"691_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108469","volume":"104","author":"B-J Chen","year":"2022","unstructured":"Chen B-J, Zhao J-W, Zhang D-H, Zheng A-H, Wu G-Q. Immunotherapy of cancer by targeting regulatory T cells. Int Immunopharmacol. 2022;104: 108469.","journal-title":"Int Immunopharmacol"},{"key":"691_CR138","doi-asserted-by":"publisher","first-page":"6852","DOI":"10.1158\/0008-5472.CAN-18-1750","volume":"78","author":"JD Freedman","year":"2018","unstructured":"Freedman JD, Duffy MR, Lei-Rossmann J, Muntzer A, Scott EM, Hagel J, et al. An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells. Cancer Res. 2018;78:6852\u201365.","journal-title":"Cancer Res"},{"key":"691_CR139","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","volume":"12","author":"A Rodriguez-Garcia","year":"2021","unstructured":"Rodriguez-Garcia A, Lynn RC, Poussin M, Eiva MA, Shaw LC, O\u2019Connor RS, et al. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat Commun. 2021;12:877.","journal-title":"Nat Commun"},{"key":"691_CR140","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/14712598.2021.1843628","volume":"21","author":"A Klampatsa","year":"2021","unstructured":"Klampatsa A, Dimou V, Albelda SM. Mesothelin-targeted CAR-T cell therapy for solid tumors. Expert Opin Biol Ther. 2021;21:473\u201386.","journal-title":"Expert Opin Biol Ther"},{"key":"691_CR141","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108542","volume":"33","author":"F Mimoto","year":"2020","unstructured":"Mimoto F, Tatsumi K, Shimizu S, Kadono S, Haraya K, Nagayasu M, et al. Exploitation of elevated extracellular ATP to specifically direct antibody to tumor microenvironment. Cell Rep. 2020;33: 108542.","journal-title":"Cell Rep"},{"key":"691_CR142","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/antib12030055","volume":"12","author":"FD Smith","year":"2023","unstructured":"Smith FD, Pierce RH, Thisted T, van der Horst EH. Conditionally active, pH-sensitive immunoregulatory antibodies targeting VISTA and CTLA-4 lead an emerging class of cancer therapeutics. Antibodies. 2023;12:55.","journal-title":"Antibodies"},{"key":"691_CR143","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s43018-023-00536-9","volume":"4","author":"F Cattaruzza","year":"2023","unstructured":"Cattaruzza F, Nazeer A, To M, Hammond M, Koski C, Liu LY, et al. Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors. Nat Cancer. 2023;4:485\u2013501.","journal-title":"Nat Cancer."},{"key":"691_CR144","doi-asserted-by":"crossref","unstructured":"Panchal A, Seto P, Wall R, Hillier BJ, Zhu Y, Krakow J, et al. COBRATM: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors. MAbs. 2020;12.(1):1792130.","DOI":"10.1080\/19420862.2020.1792130"},{"key":"691_CR145","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","volume":"9","author":"S Zhou","year":"2021","unstructured":"Zhou S, Liu M, Ren F, Meng X, Yu J. The landscape of bispecific T cell engager in cancer treatment. Biomark Res. 2021;9:38.","journal-title":"Biomark Res."},{"key":"691_CR146","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/14712598.2022.2098674","volume":"22","author":"TT Chen","year":"2022","unstructured":"Chen TT. Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development. Expert Opin Biol Ther. 2022;22:955\u201363.","journal-title":"Expert Opin Biol Ther"},{"key":"691_CR147","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1021\/acscentsci.0c01448","volume":"7","author":"R Lucchi","year":"2021","unstructured":"Lucchi R, Bentanachs J, Oller-Salvia B. The masking game: design of activatable antibodies and mimetics for selective therapeutics and cell control. ACS Cent Sci. 2021;7:724\u201338.","journal-title":"ACS Cent Sci"},{"key":"691_CR148","doi-asserted-by":"crossref","unstructured":"Walseng E, Wang B, Yang C, Patel P, Zhao C, Zhang H, et al. Conformation-selective rather than avidity-based binding to tumor associated antigen derived peptide-MHC enables targeting of WT1-pMHC low expressing cancer cells by anti-WT1-pMHC\/CD3 T cell engagers. Front Immunol. 2023;14:1275304.","DOI":"10.3389\/fimmu.2023.1275304"},{"key":"691_CR149","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41587-022-01567-w","volume":"41","author":"X Yang","year":"2023","unstructured":"Yang X, Nishimiya D, L\u00f6chte S, Jude KM, Borowska M, Savvides CS, et al. Facile repurposing of peptide\u2013MHC-restricted antibodies for cancer immunotherapy. Nat Biotechnol. 2023;41:932\u201343.","journal-title":"Nat Biotechnol"},{"key":"691_CR150","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1158\/1538-7445.AM2024-2373","volume":"84","author":"D Tortora","year":"2024","unstructured":"Tortora D, Bergqvist P, Goodman A, Blackler R, Blamey N, Carrara S, et al. Abstract 2373: Functional and specific T-cell engagers against a peptide-MHC tumor target. Cancer Res. 2024;84:2373\u20132373.","journal-title":"Cancer Res"},{"key":"691_CR151","first-page":"7123","volume":"50","author":"IG de Palazzo","year":"1990","unstructured":"de Palazzo IG, Gercel-Taylor C, Kitson J, Weiner LM. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes. Cancer Res. 1990;50:7123\u20138.","journal-title":"Cancer Res"},{"key":"691_CR152","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.4049\/jimmunol.139.9.3153","volume":"139","author":"JA Titus","year":"1987","unstructured":"Titus JA, Perez P, Kaubisch A, Garrido MA, Segal DM. Human K\/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J Immunol. 1987;139:3153\u20138.","journal-title":"J Immunol"},{"key":"691_CR153","doi-asserted-by":"publisher","unstructured":"Bottino C, Picant V, Vivier E, Castriconi R. Natural killer cells and engagers: powerful weapons against cancer. Immunol Rev. 2024. https:\/\/doi.org\/10.1111\/imr.13384.","DOI":"10.1111\/imr.13384"},{"key":"691_CR154","doi-asserted-by":"crossref","unstructured":"Xiao X, Cheng Y, Zheng X, Fang Y, Zhang Y, Sun R, et al. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager. Front Immunol. 2023;14:1113303","DOI":"10.3389\/fimmu.2023.1113303"},{"key":"691_CR155","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-015-0188-3","volume":"8","author":"J Wu","year":"2015","unstructured":"Wu J, Fu J, Zhang M, Liu D. AFM13: a first-in-class tetravalent bispecific anti-CD30\/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol. 2015;8:96.","journal-title":"J Hematol Oncol"},{"key":"691_CR156","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000971464.68430.62","volume":"7","author":"W-S Kim","year":"2023","unstructured":"Kim W-S, Shortt J, Luigi Zinzani P, Mikhaylova N, Marin-Niebla A, Radeski D, et al. P1142: AFM13 in patients with R\/R peripheral T cell lymphoma (PTCL): a post-hoc subgroup analysis from the REDIRECT study. Hemasphere. 2023;7: e6843062.","journal-title":"Hemasphere."},{"key":"691_CR157","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1080\/10428194.2022.2095623","volume":"63","author":"S Sasse","year":"2022","unstructured":"Sasse S, Br\u00f6ckelmann PJ, Momotow J, Pl\u00fctschow A, H\u00fcttmann A, Basara N, et al. AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial. Leuk Lymphoma. 2022;63:1871\u20138.","journal-title":"Leuk Lymphoma"},{"key":"691_CR158","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood.2019004701","volume":"136","author":"NL Bartlett","year":"2020","unstructured":"Bartlett NL, Herrera AF, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020;136:2401\u20139.","journal-title":"Blood"},{"key":"691_CR159","doi-asserted-by":"crossref","unstructured":"Nieto Y, B P, K I, et al. Innate cell engager (ICR\u00ae) AFM13 combined with preactivated and expanded cord blood-derived NK cells for patients with refractory\/relapsed CD30+ lymphoma. AACR Annual Meeting 2022 Abstract CT003. 2022.","DOI":"10.1158\/1538-7445.AM2022-CT003"},{"key":"691_CR160","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","volume":"21","author":"L Tong","year":"2022","unstructured":"Tong L, Jim\u00e9nez-Cortegana C, Tay AHM, Wickstr\u00f6m S, Galluzzi L, Lundqvist A. NK cells and solid tumors: therapeutic potential and persisting obstacles. Mol Cancer. 2022;21:206.","journal-title":"Mol Cancer"},{"key":"691_CR161","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/ijms23010164","volume":"23","author":"G Lian","year":"2021","unstructured":"Lian G, Mak TS-K, Yu X, Lan H-Y. Challenges and recent advances in NK cell-targeted immunotherapies in solid tumors. Int J Mol Sci. 2021;23:164.","journal-title":"Int J Mol Sci"},{"key":"691_CR162","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1200\/JCO.2023.41.16_suppl.2533","volume":"41","author":"AB El-Khoueiry","year":"2023","unstructured":"El-Khoueiry AB, Rivas D, Lee S-H, Thomas JS, Kim YJ, Cervantes A, et al. Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: interim results for the non-small cell lung cancer (NSCLC) cohort. J Clin Oncol. 2023;41:2533\u20132533.","journal-title":"J Clin Oncol"},{"key":"691_CR163","first-page":"1758","volume":"10","author":"L Uharek","year":"1996","unstructured":"Uharek L, Zeis M, Glass B, Steinmann J, Dreger P, Gassmann W, et al. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2. Leukemia. 1996;10:1758\u201364.","journal-title":"Leukemia"},{"key":"691_CR164","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1182\/blood-2001-12-0293","volume":"100","author":"MA Cooper","year":"2002","unstructured":"Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 2002;100:3633\u20138.","journal-title":"Blood"},{"key":"691_CR165","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1074-7613(00)80543-9","volume":"8","author":"K Takeda","year":"1998","unstructured":"Takeda K, Tsutsui H, Yoshimoto T, Adachi O, Yoshida N, Kishimoto T, et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity. 1998;8:383\u201390.","journal-title":"Immunity"},{"key":"691_CR166","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1365-2567.2007.02730.x","volume":"123","author":"K Skak","year":"2008","unstructured":"Skak K, Frederiksen KS, Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology. 2008;123:575\u201383.","journal-title":"Immunology"},{"key":"691_CR167","doi-asserted-by":"publisher","first-page":"S889","DOI":"10.1016\/j.annonc.2022.07.881","volume":"33","author":"JS Miller","year":"2022","unstructured":"Miller JS, Zorko N, Merino A, Phung G, Khaw M, Howard P, et al. 755P B7H3-targeted tri-specific killer engagers deliver IL-15 to NK cells but not T-cells, and specifically target solid tumors as a pan-tumor antigen strategy mediated through NK cells. Ann Oncol. 2022;33:S889.","journal-title":"Ann Oncol"},{"key":"691_CR168","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1182\/blood.V126.23.232.232","volume":"126","author":"JS Miller","year":"2015","unstructured":"Miller JS, Felice M, McElmurry R, McCullar V, Zhou X, Tolar J, et al. Trispecific killer rngagers (TriKEs) that contain IL-15 to make NK cells antigen specific and to sustain their persistence and expansion. Blood. 2015;126:232\u2013232.","journal-title":"Blood"},{"key":"691_CR169","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1158\/2326-6066.CIR-19-0837","volume":"8","author":"M Felices","year":"2020","unstructured":"Felices M, Lenvik TR, Kodal B, Lenvik AJ, Hinderlie P, Bendzick LE, et al. Potent cytolytic activity and specific IL15 delivery in a second-generation trispecific killer engager. Cancer Immunol Res. 2020;8:1139\u201349.","journal-title":"Cancer Immunol Res"},{"key":"691_CR170","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1016\/j.ymthe.2021.06.018","volume":"29","author":"E Chiu","year":"2021","unstructured":"Chiu E, Felices M, Cichocki F, Davis Z, Wang H, Tuninga K, et al. Anti-NKG2C\/IL-15\/anti-CD33 killer engager directs primary and iPSC-derived NKG2C+ NK cells to target myeloid leukemia. Mol Ther. 2021;29:3410\u201321.","journal-title":"Mol Ther"},{"key":"691_CR171","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2020-136398","volume":"136","author":"ED Warlick","year":"2020","unstructured":"Warlick ED, Weisdorf DJ, Vallera DA, Wangen R, Lewis D, Knox J, et al. GTB-3550 TriKETM for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory\/relapsed acute myeloid leukemia (AML) safely drives natural killer (NK) cell proliferation at initial dose cohorts. Blood. 2020;136:7\u20138.","journal-title":"Blood"},{"key":"691_CR172","doi-asserted-by":"crossref","unstructured":"Fenis A, Demaria O, Gauthier L, Vivier E, Narni-Mancinelli E. New immune cell engagers for cancer immunotherapy. Nat Rev Immunol. 2024.24(7):471-486.","DOI":"10.1038\/s41577-023-00982-7"},{"key":"691_CR173","doi-asserted-by":"crossref","unstructured":"Feng Y, Huang C, Wang Y, Chen J. SIRP\u03b1: a key player in innate immunity. Eur J Immunol. 2023;53(11):e2350375.","DOI":"10.1002\/eji.202350375"},{"key":"691_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100070","volume":"13","author":"R Maute","year":"2022","unstructured":"Maute R, Xu J, Weissman IL. CD47\u2013SIRP\u03b1-targeted therapeutics: status and prospects. Immuno-Oncol Technol. 2022;13: 100070.","journal-title":"Immuno-Oncol Technol."},{"key":"691_CR175","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40164-022-00279-w","volume":"11","author":"X Chauchet","year":"2022","unstructured":"Chauchet X, Cons L, Chatel L, Daubeuf B, Didelot G, Moine V, et al. CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model. Exp Hematol Oncol. 2022;11:26.","journal-title":"Exp Hematol Oncol"},{"key":"691_CR176","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.ymthe.2021.01.006","volume":"29","author":"K Du","year":"2021","unstructured":"Du K, Li Y, Liu J, Chen W, Wei Z, Luo Y, et al. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC. Mol Ther. 2021;29:1572\u201384.","journal-title":"Mol Ther"},{"key":"691_CR177","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","volume":"572","author":"AA Barkal","year":"2019","unstructured":"Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572:392\u20136.","journal-title":"Nature"},{"key":"691_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2023.100747","volume":"31","author":"Y Yang","year":"2023","unstructured":"Yang Y, Wu H, Yang Y, Kang Y, He R, Zhou B, et al. Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy. Mol Ther Oncol. 2023;31: 100747.","journal-title":"Mol Ther Oncol."},{"key":"691_CR179","doi-asserted-by":"crossref","unstructured":"Brandsma AM, Bondza S, Evers M, Koutstaal R, Nederend M, Jansen JHM, et al. Potent Fc receptor signaling by IgA leads to superior killing of cancer cells by neutrophils compared to IgG. Front Immunol. 2019;10:704.","DOI":"10.3389\/fimmu.2019.00704"},{"key":"691_CR180","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005447","volume":"10","author":"L Xu","year":"2022","unstructured":"Xu L, Li B, Pi C, Zhu Z, Tao F, Xie K, et al. Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade. J Immunother Cancer. 2022;10: e005447.","journal-title":"J Immunother Cancer"},{"key":"691_CR181","doi-asserted-by":"crossref","unstructured":"Sung P-S, Chang W-C, Hsieh S-L. CLEC5A: a promiscuous pattern recognition receptor to microbes and beyond. 2020. 1204:57\u201373.","DOI":"10.1007\/978-981-15-1580-4_3"},{"key":"691_CR182","doi-asserted-by":"crossref","unstructured":"Kedage V, Ellerman D, Fei M, Liang W-C, Zhang G, Cheng E, et al. CLEC5a-directed bispecific antibody for effective cellular phagocytosis. MAbs. 2022;14(1):2040083.","DOI":"10.1080\/19420862.2022.2040083"},{"key":"691_CR183","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s40425-019-0794-7","volume":"7","author":"MA Taylor","year":"2019","unstructured":"Taylor MA, Hughes AM, Walton J, Coenen-Stass AML, Magiera L, Mooney L, et al. Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery. J Immunother Cancer. 2019;7:328.","journal-title":"J Immunother Cancer"},{"key":"691_CR184","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1189\/jlb.3HI1114-531R","volume":"98","author":"\u00c9 Gonz\u00e1lez-Dom\u00ednguez","year":"2015","unstructured":"Gonz\u00e1lez-Dom\u00ednguez \u00c9, Samaniego R, Flores-Sevilla JL, Campos-Campos SF, G\u00f3mez-Campos G, Salas A, et al. CD163L1 and CLEC5A discriminate subsets of human resident and inflammatory macrophages in vivo. J Leukoc Biol. 2015;98:453\u201366.","journal-title":"J Leukoc Biol"},{"key":"691_CR185","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1158\/1078-0432.CCR-10-2047","volume":"17","author":"EP Buddingh","year":"2011","unstructured":"Buddingh EP, Kuijjer ML, Duim RAJ, B\u00fcrger H, Agelopoulos K, Myklebost O, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res. 2011;17:2110\u20139.","journal-title":"Clin Cancer Res"},{"key":"691_CR186","first-page":"1","volume":"2010","author":"P Allavena","year":"2010","unstructured":"Allavena P, Chieppa M, Bianchi G, Solinas G, Fabbri M, Laskarin G, et al. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin Dev Immunol. 2010;2010:1\u201310.","journal-title":"Clin Dev Immunol"},{"key":"691_CR187","doi-asserted-by":"crossref","unstructured":"Chen R, Wu W, Chen S-Y, Liu Z-Z, Wen Z-P, Yu J, et al. A pan-cancer analysis reveals CLEC5A as a biomarker for cancer immunity and prognosis. Front Immunol. 2022;13:831542.","DOI":"10.3389\/fimmu.2022.831542"},{"key":"691_CR188","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001536","volume":"9","author":"A Gao","year":"2021","unstructured":"Gao A, Liu X, Lin W, Wang J, Wang S, Si F, et al. Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity. J Immunother Cancer. 2021;9: e001536.","journal-title":"J Immunother Cancer"},{"key":"691_CR189","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.1172\/JCI97570","volume":"128","author":"H-M Chen","year":"2018","unstructured":"Chen H-M, van der Touw W, Wang YS, Kang K, Mai S, Zhang J, et al. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J Clin Invest. 2018;128:5647\u201362.","journal-title":"J Clin Invest"},{"key":"691_CR190","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1158\/1535-7163.MCT-22-0351","volume":"22","author":"B Umiker","year":"2023","unstructured":"Umiker B, Hashambhoy-Ramsay Y, Smith J, Rahman T, Mueller A, Davidson R, et al. Inhibition of LILRB2 by a novel blocking antibody designed to reprogram immunosuppressive macrophages to drive T-cell activation in tumors. Mol Cancer Ther. 2023;22:471\u201384.","journal-title":"Mol Cancer Ther"},{"key":"691_CR191","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1158\/1078-0432.CCR-21-2160","volume":"28","author":"LL Siu","year":"2022","unstructured":"Siu LL, Wang D, Hilton J, Geva R, Rasco D, Perets R, et al. First-in-class anti-immunoglobulin-like transcript 4 myeloid-specific antibody MK-4830 abrogates a PD-1 resistance mechanism in patients with advanced solid tumors. Clin Cancer Res. 2022;28:57\u201370.","journal-title":"Clin Cancer Res"},{"key":"691_CR192","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/immuno3030018","volume":"3","author":"MB Murphy","year":"2023","unstructured":"Murphy MB, Vitale L, Xia S, Peng Z, O\u2019Neill T, Lillquist J, et al. CDX-585, a bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways. Immuno. 2023;3:273\u201388.","journal-title":"Immuno"},{"key":"691_CR193","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1158\/1538-7445.AM2024-2729","volume":"84","author":"A Haight","year":"2024","unstructured":"Haight A, Chen Q, William B, Nguyen D-D, Cai R, Ma J, et al. Abstract 2729: discovery and characterization of LILRB2XPD-L1 bispecific antibody SPX-303. Cancer Res. 2024;84:2729\u20132729.","journal-title":"Cancer Res"},{"key":"691_CR194","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.1158\/1078-0432.CCR-12-1451","volume":"19","author":"CT Cummings","year":"2013","unstructured":"Cummings CT, DeRyckere D, Earp HS, Graham DK. Molecular pathways: MERTK signaling in cancer. Clin Cancer Res. 2013;19:5275\u201380.","journal-title":"Clin Cancer Res"},{"key":"691_CR195","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1189\/jlb.0909610","volume":"87","author":"F Alciato","year":"2010","unstructured":"Alciato F, Sainaghi PP, Sola D, Castello L, Avanzi GC. TNF-\u03b1, IL-6, and IL-1 expression is inhibited by GAS6 in monocytes\/macrophages. J Leukoc Biol. 2010;87:869\u201375.","journal-title":"J Leukoc Biol"},{"key":"691_CR196","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1100\/2012\/756357","volume":"2012","author":"JM Rubio-Perez","year":"2012","unstructured":"Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer\u2019s disease, role of cytokines. Sci World J. 2012;2012:1\u201315.","journal-title":"Sci World J"},{"key":"691_CR197","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1038\/s41591-022-01926-9","volume":"28","author":"H Jung","year":"2022","unstructured":"Jung H, Lee SY, Lim S, Choi HR, Choi Y, Kim M, et al. Anti-inflammatory clearance of amyloid-\u03b2 by a chimeric Gas6 fusion protein. Nat Med. 2022;28:1802\u201312.","journal-title":"Nat Med"},{"key":"691_CR198","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2021.101481","volume":"52","author":"AE Marciscano","year":"2021","unstructured":"Marciscano AE, Anandasabapathy N. The role of dendritic cells in cancer and anti-tumor immunity. Semin Immunol. 2021;52: 101481.","journal-title":"Semin Immunol"},{"key":"691_CR199","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56:2188\u2013205.","journal-title":"Immunity"},{"key":"691_CR200","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41423-021-00734-4","volume":"19","author":"TNJ Bullock","year":"2022","unstructured":"Bullock TNJ. CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies. Cell Mol Immunol. 2022;19:14\u201322.","journal-title":"Cell Mol Immunol"},{"key":"691_CR201","doi-asserted-by":"crossref","unstructured":"Salomon R, Dahan R. Next generation CD40 agonistic antibodies for cancer immunotherapy. Front Immunol. 2022;13:940674.","DOI":"10.3389\/fimmu.2022.940674"},{"key":"691_CR202","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s43018-022-00329-6","volume":"3","author":"R Salomon","year":"2022","unstructured":"Salomon R, Rotem H, Katzenelenbogen Y, Weiner A, Cohen Saban N, Feferman T, et al. Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting. Nat Cancer. 2022;3:287\u2013302.","journal-title":"Nat Cancer."},{"key":"691_CR203","first-page":"4036","volume":"27","author":"E Sum","year":"2021","unstructured":"Sum E, Rapp M, Fr\u00f6bel P, Le Clech M, D\u00fcrr H, Giusti AM, et al. Fibroblast activation protein \u03b1-targeted CD40 agonism abrogates systemic toxicity and enables administration of high doses to induce effective antitumor immunity. ClinCancer Res. 2021;27:4036\u201353.","journal-title":"ClinCancer Res."},{"key":"691_CR204","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cell.2023.12.011","volume":"187","author":"Y Shapir Itai","year":"2024","unstructured":"Shapir Itai Y, Barboy O, Salomon R, Bercovich A, Xie K, Winter E, et al. Bispecific dendritic-T cell engager potentiates anti-tumor immunity. Cell. 2024;187:375-389.e18.","journal-title":"Cell"},{"key":"691_CR205","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.1158\/0008-5472.CAN-16-0431","volume":"76","author":"P Tsou","year":"2016","unstructured":"Tsou P, Katayama H, Ostrin EJ, Hanash SM. The emerging role of B cells in tumor immunity. Cancer Res. 2016;76:5597\u2013601.","journal-title":"Cancer Res"},{"key":"691_CR206","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.4049\/jimmunol.1001323","volume":"185","author":"BH Nelson","year":"2010","unstructured":"Nelson BH. CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol. 2010;185:4977\u201382.","journal-title":"J Immunol"},{"key":"691_CR207","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/cmi.2017.35","volume":"14","author":"A Sarvaria","year":"2017","unstructured":"Sarvaria A, Madrigal JA, Saudemont A. B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol. 2017;14:662\u201374.","journal-title":"Cell Mol Immunol"},{"key":"691_CR208","doi-asserted-by":"crossref","unstructured":"Musette P, Bouaziz JD. B cell modulation strategies in autoimmune diseases: new concepts. Front Immunol. 2018;9:622.","DOI":"10.3389\/fimmu.2018.00622"},{"key":"691_CR209","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/25785826.2019.1660038","volume":"42","author":"T Tsubata","year":"2019","unstructured":"Tsubata T. Inhibitory B cell co-receptors and autoimmune diseases. Immunol Med. 2019;42:108\u201316.","journal-title":"Immunol Med"},{"key":"691_CR210","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1016\/j.molimm.2008.06.027","volume":"45","author":"SY Chu","year":"2008","unstructured":"Chu SY, Vostiar I, Karki S, Moore GL, Lazar GA, Pong E, et al. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and Fc\u03b3RIIb with Fc-engineered antibodies. Mol Immunol. 2008;45:3926\u201333.","journal-title":"Mol Immunol"},{"key":"691_CR211","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/art.27477","volume":"62","author":"M Veri","year":"2010","unstructured":"Veri M, Burke S, Huang L, Li H, Gorlatov S, Tuaillon N, et al. Therapeutic control of B cell activation via recruitment of Fc\u03b3 receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum. 2010;62:1933\u201343.","journal-title":"Arthritis Rheum"},{"key":"691_CR212","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.ebiom.2015.05.028","volume":"2","author":"G Kolumam","year":"2015","unstructured":"Kolumam G, Chen MZ, Tong R, Zavala-Solorio J, Kates L, van Bruggen N, et al. Sustained brown fat stimulation and insulin sensitization by a humanized bispecific antibody agonist for fibroblast growth factor receptor 1\/\u03b2Klotho complex. EBioMedicine. 2015;2:730\u201343.","journal-title":"EBioMedicine"},{"key":"691_CR213","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/nm.2942","volume":"18","author":"T Kitazawa","year":"2012","unstructured":"Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18:1570\u20134.","journal-title":"Nat Med"},{"key":"691_CR214","doi-asserted-by":"publisher","unstructured":"Atallah-Yunes SA, Robertson MJ. Cytokine based immunotherapy for cancer and lymphoma: biology, challenges and future perspectives. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.872010","DOI":"10.3389\/fimmu.2022.872010"},{"key":"691_CR215","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114112","volume":"182","author":"PG Holder","year":"2022","unstructured":"Holder PG, Lim SA, Huang CS, Sharma P, Dagdas YS, Bulutoglu B, et al. Engineering interferons and interleukins for cancer immunotherapy. Adv Drug Deliv Rev. 2022;182: 114112.","journal-title":"Adv Drug Deliv Rev"},{"key":"691_CR216","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2019.05.007","volume":"47","author":"DM Floss","year":"2019","unstructured":"Floss DM, Scheller J. Naturally occurring and synthetic constitutive-active cytokine receptors in disease and therapy. Cytokine Growth Factor Rev. 2019;47:1\u201320.","journal-title":"Cytokine Growth Factor Rev"},{"key":"691_CR217","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1182\/blood-2002-10-3089","volume":"101","author":"P Hu","year":"2003","unstructured":"Hu P, Mizokami M, Ruoff G, Khawli LA, Epstein AL. Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity. Blood. 2003;101:4853\u201361.","journal-title":"Blood"},{"key":"691_CR218","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/cei\/uxac105","volume":"211","author":"F Harris","year":"2023","unstructured":"Harris F, Berdugo YA, Tree T. IL-2-based approaches to Treg enhancement. Clin Exp Immunol. 2023;211:149\u201363.","journal-title":"Clin Exp Immunol"},{"key":"691_CR219","doi-asserted-by":"publisher","first-page":"10592","DOI":"10.1038\/s41598-021-90096-8","volume":"11","author":"KE Harris","year":"2021","unstructured":"Harris KE, Lorentsen KJ, Malik-Chaudhry HK, Loughlin K, Basappa HM, Hartstein S, et al. A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells. Sci Rep. 2021;11:10592.","journal-title":"Sci Rep"},{"key":"691_CR220","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1189\/jlb.5RU0714-360RR","volume":"97","author":"M Fabbi","year":"2015","unstructured":"Fabbi M, Carbotti G, Ferrini S. Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. J Leukoc Biol. 2015;97:665\u201375.","journal-title":"J Leukoc Biol"},{"key":"691_CR221","doi-asserted-by":"crossref","unstructured":"Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013;4:289.","DOI":"10.3389\/fimmu.2013.00289"},{"key":"691_CR222","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.2174\/092986710793176348","volume":"17","author":"S Srivastava","year":"2010","unstructured":"Srivastava S, Salim N, Robertson M. Interleukin-18: biology and role in the immunotherapy of cancer. Curr Med Chem. 2010;17:3353\u20137.","journal-title":"Curr Med Chem"},{"key":"691_CR223","doi-asserted-by":"crossref","unstructured":"Lipinski B, Unmuth L, Arras P, Becker S, Bauer C, Toleikis L, et al. Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition. MAbs. 2023;15 (1):2236265.","DOI":"10.1080\/19420862.2023.2236265"},{"key":"691_CR224","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.cell.2022.02.025","volume":"185","author":"M Yen","year":"2022","unstructured":"Yen M, Ren J, Liu Q, Glassman CR, Sheahan TP, Picton LK, et al. Facile discovery of surrogate cytokine agonists. Cell. 2022;185:1414-1430.e19.","journal-title":"Cell"},{"key":"691_CR225","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1021\/jacs.0c10008","volume":"143","author":"AD Cotton","year":"2021","unstructured":"Cotton AD, Nguyen DP, Gramespacher JA, Seiple IB, Wells JA. Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1. J Am Chem Soc. 2021;143:593\u20138.","journal-title":"J Am Chem Soc"},{"key":"691_CR226","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1021\/acschembio.2c00185","volume":"17","author":"JA Gramespacher","year":"2022","unstructured":"Gramespacher JA, Cotton AD, Burroughs PWW, Seiple IB, Wells JA. Roadmap for optimizing and broadening antibody-based PROTACs for degradation of cell surface proteins. ACS Chem Biol. 2022;17:1259\u201368.","journal-title":"ACS Chem Biol"},{"key":"691_CR227","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41586-022-05235-6","volume":"610","author":"H Marei","year":"2022","unstructured":"Marei H, Tsai W-TK, Kee Y-S, Ruiz K, He J, Cox C, et al. Antibody targeting of E3 ubiquitin ligases for receptor degradation. Nature. 2022;610:182\u20139.","journal-title":"Nature"},{"key":"691_CR228","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1398-9995.2004.00332.x","volume":"59","author":"SW Tam","year":"2004","unstructured":"Tam SW, Demissie S, Thomas D, Da\u00ebron M. A bispecific antibody against human IgE and human Fc \u03b3 RII that inhibits antigen-induced histamine release by human mast cells and basophils. Allergy. 2004;59:772\u201380.","journal-title":"Allergy"},{"key":"691_CR229","doi-asserted-by":"publisher","first-page":"20850","DOI":"10.1074\/jbc.M110.113910","volume":"285","author":"J Jackman","year":"2010","unstructured":"Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, et al. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem. 2010;285:20850\u20139.","journal-title":"J Biol Chem"},{"key":"691_CR230","doi-asserted-by":"publisher","first-page":"6064","DOI":"10.4049\/jimmunol.180.9.6064","volume":"180","author":"I Bachelet","year":"2008","unstructured":"Bachelet I, Munitz A, Berent-Maoz B, Mankuta D, Levi-Schaffer F. Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a. J Immunol. 2008;180:6064\u20139.","journal-title":"J Immunol"},{"key":"691_CR231","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41586-020-2851-2","volume":"586","author":"RA Fernandes","year":"2020","unstructured":"Fernandes RA, Su L, Nishiga Y, Ren J, Bhuiyan AM, Cheng N, et al. Immune receptor inhibition through enforced phosphatase recruitment. Nature. 2020;586:779\u201384.","journal-title":"Nature"},{"key":"691_CR232","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1021\/acssynbio.2c00337","volume":"11","author":"J Ren","year":"2022","unstructured":"Ren J, Jo Y, Picton LK, Su LL, Raulet DH, Garcia KC. Induced CD45 proximity potentiates natural killer cell receptor antagonism. ACS Synth Biol. 2022;11:3426\u201339.","journal-title":"ACS Synth Biol"},{"key":"691_CR233","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.1039\/D3CC01137B","volume":"59","author":"W Li","year":"2023","unstructured":"Li W, Lu W, Liu Z. A phosphatase-recruiting bispecific antibody-aptamer chimera for enhanced suppression of tumor growth. Chem Commun. 2023;59:6572\u20135.","journal-title":"Chem Commun"},{"key":"691_CR234","doi-asserted-by":"publisher","first-page":"22326","DOI":"10.1074\/jbc.271.37.22326","volume":"271","author":"AC Lankester","year":"1996","unstructured":"Lankester AC, Rood PML, van Schijndel GMW, Hooibrink B, Verhoeven AJ, van Lier RAW. Alteration of B-cell antigen receptor signaling by CD19 Co-ligation. J Biol Chem. 1996;271:22326\u201330.","journal-title":"J Biol Chem"},{"key":"691_CR235","doi-asserted-by":"crossref","unstructured":"Gartshteyn Y, Askanase AD, Song R, Bukhari S, Dragovich M, Adam K, et al. SLAMF6 compartmentalization enhances T cell functions. Life Sci Alliance. 2023;6(2):e202201533.","DOI":"10.26508\/lsa.202201533"},{"key":"691_CR236","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1080\/19420862.2019.1625662","volume":"11","author":"Y Yang","year":"2019","unstructured":"Yang Y, Yeh SH, Madireddi S, Matochko WL, Gu C, Pacheco Sanchez P, et al. Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members. MAbs. 2019;11:996\u20131011.","journal-title":"MAbs"},{"key":"691_CR237","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.chembiol.2024.03.010","volume":"31","author":"HS Jhajj","year":"2024","unstructured":"Jhajj HS, Schardt JS, Khalasawi N, Yao EL, Lwo TS, Kwon N-Y, et al. Facile generation of biepitopic antibodies with intrinsic agonism for activating tumor necrosis factor receptors. Cell Chem Biol. 2024;31:944-954.e5.","journal-title":"Cell Chem Biol"},{"key":"691_CR238","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/s42003-023-05326-8","volume":"6","author":"H Akiba","year":"2023","unstructured":"Akiba H, Fujita J, Ise T, Nishiyama K, Miyata T, Kato T, et al. Development of a 1:1-binding biparatopic anti-TNFR2 antagonist by reducing signaling activity through epitope selection. Commun Biol. 2023;6:987.","journal-title":"Commun Biol."},{"key":"691_CR239","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41408-020-0292-7","volume":"10","author":"SC Oostindie","year":"2020","unstructured":"Oostindie SC, van der Horst HJ, Kil LP, Strumane K, Overdijk MB, van den Brink EN, et al. DuoHexaBody-CD37\u00ae, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. Blood Cancer J. 2020;10:30.","journal-title":"Blood Cancer J"},{"key":"691_CR240","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/antib9030049","volume":"9","author":"J Cheng","year":"2020","unstructured":"Cheng J, Liang M, Carvalho MF, Tigue N, Faggioni R, Roskos LK, et al. Molecular mechanism of HER2 rapid internalization and redirected trafficking induced by anti-HER2 biparatopic antibody. Antibodies. 2020;9:49.","journal-title":"Antibodies"},{"key":"691_CR241","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1038\/s41467-021-23948-6","volume":"12","author":"F Kast","year":"2021","unstructured":"Kast F, Schwill M, St\u00fcber JC, Pfundstein S, Nagy-Davidescu G, Rodr\u00edguez JMM, et al. Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action. Nat Commun. 2021;12:3790.","journal-title":"Nat Commun"},{"key":"691_CR242","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccell.2015.12.008","volume":"29","author":"JY Li","year":"2016","unstructured":"Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell. 2016;29:117\u201329.","journal-title":"Cancer Cell"},{"key":"691_CR243","doi-asserted-by":"publisher","unstructured":"Bogen JP, Carrara SC, Fiebig D, Grzeschik J, Hock B, Kolmar H. Expeditious generation of biparatopic common light chain antibodies via chicken immunization and yeast display screening. Front Immunol. 2020;11. https:\/\/doi.org\/10.3389\/fimmu.2020.606878.","DOI":"10.3389\/fimmu.2020.606878"},{"key":"691_CR244","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-021-00666-5","volume":"6","author":"J Fan","year":"2021","unstructured":"Fan J, Zhuang X, Yang X, Xu Y, Zhou Z, Pan L, et al. A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models. Signal Transduct Target Ther. 2021;6:320.","journal-title":"Signal Transduct Target Ther"},{"key":"691_CR245","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1158\/1078-0432.CCR-22-2180","volume":"29","author":"SY Oh","year":"2023","unstructured":"Oh SY, Lee YW, Lee EJ, Kim JH, Park Y, Heo SG, et al. Preclinical study of a biparatopic METxMET antibody\u2013drug conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC. Clin Cancer Res. 2023;29:221\u201332.","journal-title":"Clin Cancer Res"},{"key":"691_CR246","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1158\/1538-7445.AM2024-3136","volume":"84","author":"Y Wu","year":"2024","unstructured":"Wu Y, Jiang B, Rivera J, Wang F, Zhou J, Liu L, et al. Abstract 3136: Towards development of a novel biparatopic trop2-ADC. Cancer Res. 2024;84:3136\u20133136.","journal-title":"Cancer Res"},{"key":"691_CR247","doi-asserted-by":"publisher","first-page":"LB045","DOI":"10.1158\/1538-7445.AM2024-LB045","volume":"84","author":"G Cotton","year":"2024","unstructured":"Cotton G, McLean EG, Trumper P, Wappett M, Gatdula S, Bell S, et al. Abstract LB045: exploiting biparatopic binding to deliver novel, differentiated ALPP\/ALPPL2 targeting protein drug conjugates. Cancer Res. 2024;84:LB045.","journal-title":"Cancer Res"},{"key":"691_CR248","doi-asserted-by":"crossref","unstructured":"Niquille DL, Fitzgerald KM, Gera N. Biparatopic antibodies: therapeutic applications and prospects. MAbs. 2024;16(1):2310890.","DOI":"10.1080\/19420862.2024.2310890"},{"key":"691_CR249","doi-asserted-by":"crossref","unstructured":"Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017. 9(2):182\u2013212.","DOI":"10.1080\/19420862.2016.1268307"},{"key":"691_CR250","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-020-2168-1","volume":"580","author":"RJ Deshaies","year":"2020","unstructured":"Deshaies RJ. Multispecific drugs herald a new era of biopharmaceutical innovation. Nature. 2020;580:329\u201338.","journal-title":"Nature"},{"key":"691_CR251","doi-asserted-by":"publisher","first-page":"7496","DOI":"10.3390\/ijms21207496","volume":"21","author":"MS Sawant","year":"2020","unstructured":"Sawant MS, Streu CN, Wu L, Tessier PM. Toward drug-like multispecific antibodies by design. Int J Mol Sci. 2020;21:7496.","journal-title":"Int J Mol Sci"},{"key":"691_CR252","doi-asserted-by":"crossref","unstructured":"Dicara DM, Bhakta S, Go MA, Ziai J, Firestein R, Forrest B, et al. Development of T-cell engagers selective for cells co-expressing two antigens. MAbs. 2022;14(1):2115213.","DOI":"10.1080\/19420862.2022.2115213"},{"key":"691_CR253","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11684-021-0835-8","volume":"16","author":"S Wang","year":"2022","unstructured":"Wang S, Peng L, Xu W, Zhou Y, Zhu Z, Kong Y, et al. Preclinical characterization and comparison between CD3\/CD19 bispecific and novel CD3\/CD19\/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia. Front Med. 2022;16:139\u201349.","journal-title":"Front Med"},{"key":"691_CR254","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2020-140154","volume":"136","author":"J Zhang","year":"2020","unstructured":"Zhang J, Zhou Z. Preclinical study of a novel tri-specific anti-CD3\/CD19\/CD20 T cell-engaging antibody as a potentially better treatment for NHL. Blood. 2020;136:22\u201322.","journal-title":"Blood"},{"key":"691_CR255","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1182\/blood-2022-168739","volume":"140","author":"A Kuchnio","year":"2022","unstructured":"Kuchnio A, Yang D, Vloemans N, Lowenstein C, Cornelissen I, Amorim R, et al. Characterization of JNJ-80948543, a novel CD79bxCD20xCD3 trispecific T-cell redirecting antibody for the treatment of B-cell non-hodgkin lymphoma. Blood. 2022;140:3105\u20136.","journal-title":"Blood"},{"key":"691_CR256","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1182\/blood.2022016243","volume":"140","author":"L Zhao","year":"2022","unstructured":"Zhao L, Li S, Wei X, Qi X, Liu D, Liu L, et al. A novel CD19\/CD22\/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. Blood. 2022;140:1790\u2013802.","journal-title":"Blood"},{"key":"691_CR257","doi-asserted-by":"publisher","unstructured":"Harwardt J, Carrara SC, Bogen JP, Schoenfeld K, Grzeschik J, Hock B, et al. Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1170042.","DOI":"10.3389\/fimmu.2023.1170042"},{"key":"691_CR258","doi-asserted-by":"crossref","unstructured":"Warwas KM, Meyer M, Gon\u00e7alves M, Moldenhauer G, Bulbuc N, Knabe S, et al. Co-stimulatory bispecific antibodies induce enhanced T cell activation and tumor cell killing in breast cancer models. Front Immunol. 2021;12:719116.","DOI":"10.3389\/fimmu.2021.719116"},{"key":"691_CR259","doi-asserted-by":"publisher","first-page":"5121","DOI":"10.1158\/1538-7445.AM2023-5121","volume":"83","author":"L Newhook","year":"2023","unstructured":"Newhook L, Bhojane PP, Repenning PW, Escanda DP, Escalante NK, Zwierzchowski P, et al. Abstract 5121: TriTCE Co-stim, next generation costimulatory trispecific T cell engagers for the treatment of solid tumors. Cancer Res. 2023;83:5121\u20135121.","journal-title":"Cancer Res"},{"key":"691_CR260","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","volume":"1","author":"L Wu","year":"2019","unstructured":"Wu L, Seung E, Xu L, Rao E, Lord DM, Wei RR, et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nat Cancer. 2019;1:86\u201398.","journal-title":"Nat Cancer."},{"key":"691_CR261","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","volume":"603","author":"E Seung","year":"2022","unstructured":"Seung E, Xing Z, Wu L, Rao E, Cortez-Retamozo V, Ospina B, et al. A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells. Nature. 2022;603:328\u201334.","journal-title":"Nature"},{"key":"691_CR262","doi-asserted-by":"publisher","first-page":"TPS2668","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2668","volume":"41","author":"J Wang","year":"2023","unstructured":"Wang J, Qi J, Li W, Zhai Z, Li P, Zou W, et al. GNC-038, a tetra-specific antibody, in patients with R\/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: a phase 1 study design and rationale. J Clin Oncol. 2023;41:TPS2668.","journal-title":"J Clin Oncol"},{"key":"691_CR263","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1158\/1538-7445.AM2023-5679","volume":"83","author":"JS Khalili","year":"2023","unstructured":"Khalili JS, Xiao S, Zhu Y. Abstract 5679: Tetra-specific antibody GNC-035: guidance and navigation control (GNC) molecule development for treatment of ROR1+ malignancies. Cancer Res. 2023;83:5679\u20135679.","journal-title":"Cancer Res"},{"key":"691_CR264","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1158\/1538-7445.AM2023-1872","volume":"83","author":"H Mikami","year":"2023","unstructured":"Mikami H, Feng S, Naoi S, Azuma Y, Kayukawa Y, Tsunenari T, et al. Abstract 1872: a DLL3\/CD3\/CD137 trispecific T cell engager shows potent antitumor activity in small cell lung cancer models. Cancer Res. 2023;83:1872\u20131872.","journal-title":"Cancer Res"},{"key":"691_CR265","doi-asserted-by":"crossref","unstructured":"Mikami H, Feng S, Matsuda Y, Ishii S, Naoi S, Azuma Y, et al. Engineering CD3\/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small-cell lung cancer. Cancer Immunol Res. 2024;12(6):719-730","DOI":"10.1158\/2326-6066.CIR-23-0638"},{"key":"691_CR266","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood-2022-168904","volume":"140","author":"H Lu","year":"2022","unstructured":"Lu H, Oka A, Coulson M, Polli JR, Aardalen K, Ramones M, et al. PIT565, a first-in-class anti-CD19, anti-CD3, anti-CD2 trispecific antibody for the treatment of B cell malignancies. Blood. 2022;140:3148\u20133148.","journal-title":"Blood"},{"key":"691_CR267","doi-asserted-by":"crossref","unstructured":"Sergeeva OA, Fearnley A, Zeiger J, Tam EM, Sarkar M, Lai Z, et al. 1386\u2005EVOLVE-106, a T cell engager with integrated CD2 costimulation targeting B7-H4, is a precision therapy for estrogen and Her2 receptor low breast cancers. Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2023. p. A1541\u2013A1541.","DOI":"10.1136\/jitc-2023-SITC2023.1386"},{"key":"691_CR268","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2217\/imt-2023-0256","volume":"16","author":"L Chen","year":"2024","unstructured":"Chen L, Qian W, Pan F, Li D, Yu W, Tong L, et al. A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3\/CD28 co-engagement. Immunotherapy. 2024;16:143\u201359.","journal-title":"Immunotherapy"},{"key":"691_CR269","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s10529-005-6732-4","volume":"27","author":"J Liu","year":"2005","unstructured":"Liu J, Zhao Q, Zhao B, Cheng J, Wang X, Song L, et al. A new format of single chain tri-specific antibody with diminished molecular size efficiently induces ovarian tumor cell killing. Biotechnol Lett. 2005;27:1821\u20137.","journal-title":"Biotechnol Lett"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00691-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00691-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00691-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T22:03:15Z","timestamp":1737496995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00691-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":269,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["691"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00691-0","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,13]]},"assertion":[{"value":"6 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was used for writing this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The author is a full-time employee of Genentech, a member of the Roche group.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}